• Neurocrine filed an amended current report to update unaudited pro forma financials tied to its Soleno acquisition, which closed May 18, 2026.
• The amendment presents pro forma combined results as if the deal closed on Jan. 1, 2025, including updated purchase accounting adjustments.
• Pro forma net income totaled $294 million for the six months ended June 30, 2026, with basic EPS of $2.92.
• Pro forma net income was $324.5 million for 2025, with basic EPS of $3.26.
• The company repaid a $600 million revolver draw by June 30, 2026, with no pro forma adjustments recorded for the borrowing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-328470), on July 31, 2026, and is solely responsible for the information contained therein.